Tag: Cancer: Prostate

Lower mortality risk seen for those who improved guideline concordance after diagnosis or maintained high concordance

Risks especially high within three months of infection

Benefits seen across participants with breast or prostate cancer, as well as postmenopausal women

Clinically significant cancer was detected in 29.2 versus 29.6 percent of men with biparametric and multiparametric MRI

Urine panel had AUC of 0.96 and 0.92 with development and validation datasets, respectively, compared with 0.83 and 0.76 for urinary PCA3 RNA

Black men have double the prostate cancer mortality and 67 percent higher incidence than White men

Prostate cancer-specific mortality rates 2.4 and 4.7 percent for unfavorable intermediate-risk and high-risk GG1

Black men fare worse in confirmatory testing and face lower likelihood of potential overtreatment

Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to six times more likely to die of other causes

Findings show promise compared with usual care but warrant a larger trial, the authors say